Home » Topics » BioWorld Science

BioWorld Science
RSS

Farxiga meets primary endpoint in landmark phase III DAPA-HF study

Aug. 20, 2019

Oxurion reports topline results from phase IIa study of THR-317 plus ranibizumab in DME

Aug. 20, 2019

FDA approves Xenleta for the treatment of community-acquired bacteria pneumonia

Aug. 20, 2019

Cephamycins treat spore-forming bacteria, prevent relapses

Aug. 20, 2019

Sarepta Therapeutics receives complete response letter for golodirsen

Aug. 20, 2019

PD-1/PD-L1 interaction inhibitors patented by Bristol-Myers Squibb

Aug. 20, 2019

RAPT Therapeutics describes new C-C chemokine receptor type 4 antagonists

Aug. 20, 2019

Exelixis discovers AXL/Mer/c-Met inhibitors

Aug. 20, 2019

SU-011 improves glycemic control in vivo without the risk of hypoglycemia and weight gain

Aug. 20, 2019

Preclinical data presented for the novel re-engineered lupus autoantibody PAT-DX1

Aug. 20, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...